Media Articles Related to Kenalog (Triamcinolone Topical)
Atopic dermatitis: Positive topline Phase 3 results announced for dupilumab
Source: Clinical Trials / Drug Trials News From Medical News Today [2016.06.06]
Regeneron Pharmaceuticals, Inc. and Sanofi have announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary...
Eczema (Atopic Dermatitis) Causes, Symptoms, Treatment
Source: MedicineNet Atopic Dermatitis Specialty [2016.05.24]
Title: Eczema (Atopic Dermatitis) Causes, Symptoms, Treatment
Created: 3/26/2012 12:00:00 AM
Last Editorial Review: 5/24/2016 12:00:00 AM
Source: MedicineNet Seborrhea Specialty [2016.03.18]
Title: Seborrheic Dermatitis
Category: Diseases and Conditions
Created: 3/16/2012 12:00:00 AM
Last Editorial Review: 3/18/2016 12:00:00 AM
Source: MedicineNet Otitis Externa Specialty [2015.10.09]
Title: Atopic Dermatitis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/9/2015 12:00:00 AM
Published Studies Related to Kenalog (Triamcinolone Topical)
Comparison of the efficacy of intralesional triamcinolone acetonide and
5-fluorouracil tattooing for the treatment of keloids. 
for treatment of keloids... CONCLUSION: 5-FU tattooing was more effective than intralesional TAC for the
Intravitreal triamcinolone versus laser photocoagulation as a primary treatment for diabetic macular oedema - a comparative pilot study. [2011.11.23]
ABSTRACT: BACKGROUND: Diabetic macular oedema is the leading causes of blindness. Laser photocoagulation reduces the risk of visual loss. However recurrences are common and despite laser treatment, patients with diabetic macular oedema experienced progressive loss of vision. Stabilization of the blood retinal barrier introduces a rationale for intravitreal triamcinolone treatment in diabetic macular oedema. This study is intended to compare the best corrected visual acuity (BCVA) and the macular oedema index (MEI) at 3 month of primary treatment for diabetic macular oedema between intravitreal triamcinolone acetonide (IVTA) and laser photocoagulation... CONCLUSIONS: IVTA demonstrates good outcome comparable to laser photocoagulation as a primary treatment for diabetic macular oedema at three months post treatment. TRIAL REGISTRATION: ISRCTN05040192 (http://www.controlled-trial.com).
Effects of intracameral triamcinolone and gentamicin injections following cataract surgery. [2011.07]
CONCLUSION: Intracameral injections of triamcinolone acetonide and gentamicin appear to be a promising treatment option for the control of post-operative inflammation following cataract surgery.
Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. [2011.06]
PURPOSE: To evaluate 14-week effects of intravitreal ranibizumab or triamcinolone in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation... CONCLUSION: The addition of 1 intravitreal triamcinolone injection or 2 intravitreal ranibizumab injections in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation is associated with better visual acuity and decreased macular edema by 14 weeks. Whether continued long-term intravitreal treatment is beneficial cannot be determined from this study.
Application of triamcinolone acetonide paste to the endotracheal tube reduces postoperative sore throat: a randomized controlled trial. [2011.05]
PURPOSE: This study was performed to examine whether applying triamcinolone acetonide paste as a lubricant to endotracheal tubes (ETTs) reduces the incidence and severity of postoperative sore throat (POST) more effectively than applying chlorhexidine gluconate jelly... CONCLUSIONS: Triamcinolone acetonide paste applied along the length of the ETT resulted in clinically important and statistically significant decreases in the incidence and severity of POST compared with the application of chlorhexidine jelly. (ClinicalTrials.gov number, NCT00908817).
Clinical Trials Related to Kenalog (Triamcinolone Topical)
Intralesional Steroids in the Treatment of Alopecia Areata [Recruiting]
Alopecia areata is a common form of hair loss which reportedly occurs in up to 1. 7% of the
population at some time in their life. Alopecia areata is apparently triggered when the
individual's own immune system attacks hair follicles on the scalp or body resulting in hair
loss ranging from single patches on the scalp (patch type alopecia areata) to loss of every
hair on the scalp and body (alopecia universalis). Currently, there are limited treatment
options for alopecia areata and unfortunately, the treatments utilized have never been
rigorously tested in a placebo controlled trial.
Triamcinolone (Kenalog) is a steroid solution that has been used as treatment for alopecia
areata for over 50 years. It is administered via injection into the scalp and appears to
have some efficacy for patients with mild to moderate alopecia areata. We currently do not
have objective data on the frequency of occurrence of successful regrowth, the duration of
response or the incidence of side effects. In addition, there is disagreement between
clinicians regarding the dose of intralesional triamcinolone (IL TAC) that is considered
This study aims to determine the frequency of response to treatment with 3 concentrations of
IL TAC, 2. 5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of
side effects compared to treatment with placebo (sterile saline solution). After the 1st 6
months non or partial responders may be treated for 6 months with open label triamcinolone
at the dose deemed appropriate by the investigator.
We will also perform skin biopsies of the scalp and draw blood at selected time points in
order to examine the immunohistochemical/pathological response in scalp hair follicles and
the systemic circulation to treatment with IL TAC for alopecia areata.
Early Treatment for Acute ACL Tear [Active, not recruiting]
This research study is the first of its kind and will allow health care professionals and
researchers to answer many questions about the reasons why anterior cruciate ligament (ACL)
injury leads to knee pain and disability and osteoarthritis. We also hope that this study
will be the beginning of new, more powerful and safer drugs to help patients with ACL
injuries heal sooner and return to sports or daily activities pain free. Study participants
will be recruited from the University of Kentucky and Vanderbilt University.
The purpose of this research is to gather information on how safe and effective Kenalog® is
in alleviating knee pain following ACL rupture.
A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema [Completed]
The study involves the enrollment of patients over 18 years of age with diabetic macular
edema involving the center of the macula who have not already been given maximal laser
Patients with one study eye will be randomly assigned (stratified by prior laser) with equal
probability to one of five treatment groups:
1. Focal laser photocoagulation (modified ETDRS technique)
2. Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
3. Anterior peribulbar injection of 20 mg triamcinolone
4. Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
5. Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
For patients with two study eyes (both eyes eligible at the time of randomization), the
right eye (stratified by prior laser) will be randomly assigned with equal probabilities to
one of the five treatment groups listed above. If the right eye was assigned to laser only,
then the left eye will be assigned to one of the four triamcinolone groups above with equal
probability (stratified by prior laser). If the right eye was assigned to receive
triamcinolone, then the left eye will receive laser only.
Triamcinolone acetonide will be the corticosteroid utilized in this study. The triamcinolone
acetonide preparation to be used is Kenalog. Kenalog is manufactured by Bristol Myers Squibb
and is approved by the Food and Drug Administration for intramuscular use for a variety of
indications. Peribulbar injections of Kenalog have been used for a wide variety of ocular
conditions, particularly uveitis and post-cataract extraction cystoid macular edema, for
Two different triamcinolone regimens will be assessed in the study: 40 mg injected
posteriorly and 20 mg injected anteriorly. There is no indication of which treatment regimen
will be better. Although the injection behind the eye is more common than the injection near
the front of the eye, the injection near the front of the eye has less risk of injuring the
eye. However, it is possible that the injection near the front of the eye may increase eye
pressure more frequently. Little is known about which of the two injections decreases
macular edema and improves vision more often.
Patients enrolled into the study will be followed for three years and will have study visits
1 month, 2 months, 4 months, 8 months and annually after receiving their assigned study
treatment. For the first 8 months of the study, patients should only be retreated with their
randomized treatment. However, if the patient's visual acuity has decreased by 15 letters or
more, then any treatment may be given at the investigator's discretion. After completion of
the 8-month visit, treatment is at investigator discretion.
The primary objective of this study is to obtain estimates of efficacy and safety outcomes
for each of the treatment groups. These estimates will provide a basis for the sample size
estimation and hypothesis generation in a phase III trial.
Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis [Recruiting]
It is currently unknown whether or not the improvement in pain and function related to a
"steroid shot" for shoulder pain due to subacromial bursitis is important. This study seeks
to determine whether 20 mg or 40 mg of either triamcinolone or methylprednisolone
significantly affect improvement in shoulder pain 6 weeks after injection.
Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain [Not yet recruiting]
The goal of this study is to compare the effectiveness of two different medications used in
intravaginal trigger point injections (injections into extremely painful areas of a muscle)
to treat chronic pelvic pain. The study compares onabotulinumtoxinA (BOTOX®) (a drug
prepared from the bacterial toxin botulin which temporarily paralyzes muscles) to Kenalog (a
synthetic corticosteroid used as an anti-inflammatory agent).
Reports of Suspected Kenalog (Triamcinolone Topical) Side Effects
Injection Site Atrophy (9),
Swelling Face (6),
Injection Site Pain (5),
Retinal Detachment (4), more >>